Radiation enteropathy-Pathogenesis, treatment and prevention

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 8, 2014, Pages 470-479

  Hauer Jensen, Martin ^a   Denham, James W ^b   Andreyev, H Jervoise N ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; G PROTEIN COUPLED RECEPTOR; GAMMA TOCOTRIENOL; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

CANCER PATIENT; CANCER RADIOTHERAPY; CELL PROLIFERATION; CLINICAL RESEARCH; GASTROENTEROLOGIST; HISTOPATHOLOGY; HUMAN; HYPOTENSION; INCIDENCE; MOLECULAR MECHANICS; NAUSEA; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION ENTEROPATHY; RADIATION EXPOSURE; RADIATION FIELD; RADIATION HAZARD; REVIEW; VOMITING;

ANIMALS; HUMANS; INTESTINAL DISEASES; NEOPLASMS; RADIOTHERAPY; RATS;

EID: 84905700706     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.46     Document Type: Review

References (105)

1. DeVita, V. T., Lawrence, T. S. & Rosenberg, S. A. DeVita, Hellman, and Rosenberg's Cancer. Principles & Practice of Oncology (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011).
2. Goitein, M. How best to dispose of extra-tumoral dose: a cautionary note for intensity-modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 75, 1-3 (2009).
3. Eifel, P. J., Jhingran, A., Bodurka, D. C., Levenback, C. & Thames, H. Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. J. Clin. Oncol. 20, 3651-3657 (2002).
4. Wedlake, L. J. et al. Predicting late effects of pelvic radiotherapy: is there a better approach? Int. J. Radiat. Oncol. Biol. Phys. 78, 1163-1170 (2010).
5. Willett, C. G. et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int. J. Radiat. Oncol. Biol. Phys. 46, 995-998 (2000).
6. Herold, D. M., Hanlon, A. L. & Hanks, G. E. Diabetes mellitus: a predictor for late radiation morbidity. Int. J. Radiat. Oncol. Biol. Phys. 43, 475-479 (1999).
7. Potish, R. A., Twiggs, L. B., Adcock, L. L. & Prem, K. A. Logistic models for prediction of enteric morbidity in the treatment of ovarian and cervical cancers. Am. J. Obstet. Gynecol. 147, 65-72 (1983).
8. Ross, J. G., Hussey, D. H., Mayr, N. A. & Davis, C. S. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer 71, 3744-3752 (1993).
9. Lin, A., Abu-Isa, E., Griffith, K. A. & Ben-Josef, E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer 113, 648-653 (2008).
10. West, C. M. & Barnett, G. C. Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med. 3, 52 (2011).
11. Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220-241 (2012).
12. Hewitt, M. E., Greenfield, S. & Stovall, E. From Cancer Patient to Cancer Survivor. Lost in Transition (National Academies Press, 2006).
13. Bentzen, S. M. et al. Normal tissue effects: reporting and analysis. Semin. Radiat. Oncol. 13, 189-202 (2003).
14. Fransson, P. & Widmark, A. 15-year prospective follow-up of patient-reported outcomes of late bowel toxicity after external beam radiotherapy for localized prostate cancer. A comparison with age-matched controls. Acta Oncol. 46, 517-524 (2007).
15. Yeoh, E. et al. Effect of pelvic irradiation on gastrointestinal function: a prospective longitudinal study. Am. J. Med. 95, 397-406 (1993).
16. Lakatos, P.-L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J. Gastroenterol. 12, 6102-6108 (2006)
17. Centers for Disease Control and Prevention Inflammatory Bowel Disease (IBD) [online], http://www.cdc.gov/ibd/(2014).
18. Hauer-Jensen, M., Poulakos, L. & Osborne, J. W. Effects of accelerated fractionation on radiation injury of the small intestine: a new rat model. Int. J. Radiat. Oncol. Biol. Phys. 14, 1205-1212 (1988).
19. Husebye, E., Hauer-Jensen, M., Kjorstad, K. & Skar, V. Severe late radiation enteropathy is characterized by impaired motility of proximal small intestine. Dig. Dis. Sci. 39, 2341-2349 (1994).
20. Vale, C. L., Tierney, J. F., Davidson, S. E., Drinkwater, K. J. & Symonds, P. Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit. Clin. Oncol. (R. Coll. Radiol.) 22, 590-601 (2010).
21. Regimbeau, J. M., Panis, Y., Gouzi, J. L. & Fagniez, P. L. Operative and long term results after surgery for chronic radiation enteritis. Am. J. Surg. 182, 237-242 (2001).
22. Larsen, A., Reitan, J. B., Aase, S. T. & Hauer-Jensen, M. Long-term prognosis in patients with severe late radiation enteropathy: a prospective cohort study. World J. Gastroenterol. 13, 3610-3613 (2007).
23. Fajardo, L. F., Berthrong, M. & Anderson, R. E. Radiation Pathology 209-248 (Oxford University Press, 2001).
24. Carr, K. E. Effects of radiation damage on intestinal morphology. Int. Rev. Cytol. 208, 1-119 (2001).
25. Hauer-Jensen, M. et al. in Human Radiation Injury Ch. 38 (eds Shrieve, D. C. & Loeffler, J. S.) 421-440 (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011).
26. Atwood, K. C. & Norman, A. On the interpretation of multi-hit survival curves. Proc. Natl Acad. Sci. USA 35, 696-709 (1949).
27. Wang, J. & Hauer-Jensen, M. Neuroimmune interactions: potential target for mitigating or treating intestinal radiation injury. Br. J. Radiol. 80 (Spec. 1), S41-S48 (2007).
28. Packey, C. D. & Ciorba, M. A. Microbial influences on the small intestinal response to radiation injury. Curr. Opin. Gastroenterol. 26, 88-94 (2010).
29. Bourne, R. G., Kearsley, J. H., Grove, W. D. & Roberts, S. J. The relationship between early and late gastrointestinal complications of radiation therapy for carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys. 9, 1445-1450 (1983).
30. Peters, L. J., Ang, K. K. & Thames, H. D. Jr. Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol. 27, 185-194 (1988).
31. Wang, J., Qiu, X., Kulkarni, A. & Hauer-Jensen, M. Calcitonin gene-related peptide and substance P regulate the intestinal radiation response. Clin. Cancer Res. 12, 4112-4118 (2006).
32. Wang, J., Zheng, H. & Hauer-Jensen, M. Influence of short-term octreotide administration on chronic tissue injury, transforming growth factor β (TGF-β) overexpression, and collagen accumulation in irradiated rat intestine. J. Pharmacol. Exp. Ther. 297, 35-42 (2001).
33. Wang, J., Zheng, H., Kulkarni, A., Ou, X. & Hauer-Jensen, M. Regulation of early and delayed radiation responses in rat small intestine by capsaicin-sensitive nerves. Int. J. Radiat. Oncol. Biol. Phys. 64, 1528-1536 (2006).
34. Zheng, H., Wang, J. & Hauer-Jensen, M. Role of mast cells in early and delayed radiation injury in rat intestine. Radiat. Res. 153, 533-539 (2000).
35. Denham, J. W., Hauer-Jensen, M. & Peters, L. J. Is it time for a new formalism to categorize normal tissue radiation injury? Int. J. Radiat. Oncol. Biol. Phys. 50, 1105-1106 (2001).
36. Denham, J. W. & Hauer-Jensen, M. The radiotherapeutic injury-a complex 'wound'. Radiother. Oncol. 63, 129-145 (2002).
37. Hovdenak, N., Fajardo, L. F. & Hauer-Jensen, M. Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 48, 1111-1117 (2000).
38. Carratu, R. et al. Assessment of small intestinal damage in patients treated with pelvic radiotherapy. Oncol. Rep. 5, 635-639 (1998).
39. Hauer-Jensen, M., Poulakos, L. & Osborne, J. W. Effects of accelerated fractionation on radiation injury of the small intestine: a new rat model. Int. J. Radiat. Oncol. Biol. Phys. 14, 1205-1212 (1988).
40. Boerma, M., Wang, J., Richter, K. K. & Hauer-Jensen, M. Orazipone, a locally acting immunomodulator, ameliorates intestinal radiation injury: a preclinical study in a novel rat model. Int. J. Radiat. Oncol. Biol. Phys. 66, 552-559 (2006).
41. Potten, C. S., Merritt, A., Hickman, J., Hall, P. & Faranda, A. Characterization of radiation-induced apoptosis in the small intestine and its biological implications. Int. J. Radiat. Biol. 65, 71-78 (1994).
42. Komarova, E. A. et al. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 23, 3265-3271 (2004).
43. Kirsch, D. G. et al. p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science 327, 593-596 (2010).
44. Leibowitz, B. J. et al. Uncoupling p53 functions in radiation-induced intestinal damage via PUMA and p21. Mol. Cancer Res. 9, 616-625 (2011).
45. Cheng, H. & Leblond, C. P. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian theory of the origin of the four epithelial cell types. Am. J. Anat. 141, 537-561 (1974).
46. Potten, C. S. Extreme sensitivity of some intestinal crypt cells to X and gamma irradiation. Nature 269, 518-521 (1977).
47. Yan, K. S. et al. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc. Natl Acad. Sci. USA 109, 466-471 (2012).
48. Hua, G. et al. Crypt base columnar stem cells in small intestines of mice are radioresistant. Gastroenterology 143, 1266-1276 (2012).
49. van Landeghem, L. et al. Activation of two distinct Sox9-EGFP-expressing intestinal stem cell populations during crypt regeneration after irradiation. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1111-G1132 (2012).
50. Metcalfe, C., Kljavin, N. M., Ybarra, R. & de Sauvage, F. J. Lgr5+ stem cells are indispensable for radiation-induced intestinal regeneration. Cell Stem Cell 14, 149-159 (2014).
51. Hopewell, J. W. et al. Microvasculature and radiation damage. Recent Results. Cancer Res. 130, 1-16 (1993).
52. Baker D. G. & Krochak, R. J. The response of the microvascular system to radiation: a review. Cancer Invest. 7, 287-294 (1989).
53. Rezvani, M., Hopewell, J. W. & Robbins, M. E. Initiation of non-neoplastic late effects: the role of endothelium and connective tissue. Stem Cells 13 (Suppl. 1), 248-256 (1995).
54. Wang, J., Zheng, H., Ou, X., Fink, L. M. & Hauer-Jensen, M. Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiated rat intestine: possible link between endothelial dysfunction and chronic radiation fibrosis. Am. J. Pathol. 160, 2063-2072 (2002).
55. Richter, K. K., Fink, L. M., Hughes, B. M., Sung, C. C. & Hauer-Jensen, M. Is the loss of endothelial thrombomodulin involved in the mechanism of chronicity in late radiation enteropathy? Radiother. Oncol. 44, 65-71 (1997).
56. Paris, F et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297 (2001).
57. Rotolo, J. et al. Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice. J. Clin. Invest. 122, 1786-1790 (2012).
58. Schuller, B. W. et al. Selective irradiation of the vascular endothelium has no effect on the survival of murine intestinal crypt stem cells. Proc. Natl Acad. Sci. USA 103, 3787-3792 (2006).
59. Schuller, B. W. et al. No significant endothelial apoptosis in the radiation-induced gastrointestinal syndrome. Int. J. Radiat. Oncol. Biol. Phys. 68, 205-210 (2007).
60. Laroux, F S. & Grisham, M. B. Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation 8, 283-301 (2001).
61. Wang, J., Boerma, M., Fu, Q. & Hauer-Jensen, M. Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy. World J. Gastroenterol. 13, 3047-3055 (2007).
62. Geiger, H. et al. Pharmacological targeting of the thrombomodulin- activated protein C pathway mitigates radiation toxicity. Nat. Med. 18, 1123-1129 (2012).
63. Shanahan, F The host-microbe interface within the gut. Best Pract. Res. Clin. Gastroenterol. 16, 915-931 (2002).
64. Robert, A. & Asano, T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 14, 333-341 (1977).
65. Osborne, J. W., Bryan, H. S., Quastler, H. & Rhoades, H. E. X-irradiation and bacteremia; studies on roentgen death in mice. IV. Am. J. Physiol. 170, 414-417 (1952).
66. Wilson, B. R. Survival studies of whole body X-irradiated germfree (axenic) mice. Radiat. Res. 20, 477-483 (1963).
67. Crawford, P. A. & Gordon, J. I. Microbial regulation of intestinal radiosensitivity. Proc. Natl Acad. Sci. USA 102, 13254-13259 (2005).
68. Delia, P. et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am. J. Gastroenterol. 97, 2150-2152 (2002).
69. Ciorba, M. A. et al. Lactobacillus probiotic protects intestinal epithelium from radiation njury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut 61, 829-838 (2012).
70. Urbancsek, H., Kazar, T., Mezes, I. & Neumann, K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus n patients with radiation-induced diarrhoea. Eur. J. Gastroenterol. Hepatol. 13, 391-396 (2001).
71. Osterlund, P. et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br. J. Cancer 97, 1028-1034 (2007).
72. Gibson, R. J. et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 21, 313-326 (2013).
73. Dave, M., Higgins, P. D., Middha, S. & Rioux, K. P. The human gut microbiome: current knowledge, challenges, and future directions. Transl. Res. 160, 246-257 (2012).
74. Lamendella, R., VerBerkmoes, N. & Jansson, J. K. 'Omics' of the mammalian gut-new insights into function. Curr. Opin. Biotechnol. 23, 491-500 (2012).
75. Damman, C. J. & Surawicz, C. M. The gut microbiota: a microbial arsenal protecting us from infectious and radiation-induced diarrhea. Gastroenterology 136, 722-724 (2009).
76. Nam, Y.-D., Kim, H. J., Seo, J.-G., Kang, S. W. & Bae, J.-W. Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PLoS ONE 8, e82659 (2013).
77. Tlaskalova-Hogenova, H. et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of nflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell. Mol. Immunol. 8, 110-120 (2011).
78. Yi, P. & Li, L. The germfree murine animal: an important animal model for research on the relationship between gut microbiota and the host. Vet. Microbiol. 157, 1-7 (2012).
79. Lalla, R. V. et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer http://dx.doi.org/ 10.1002/cncr.28592.
80. Nicolatou-Galitis, O. et al. Systematic review of amifostine for the management of oral mucositis n cancer patients. Support Care Cancer 21, 357-364 (2013).
81. Andreyev, H. J. N., Davidson, S. E., Gillespie, C, Allum, W. H. & Swarbrick, E. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut 61, 179-192 (2011).
82. Kochhar, R. et al. Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig. Dis. Sci. 36, 103-107 (1991).
83. Sanguineti, G., Franzone, P., Marcenaro, M., Foppiano, F & Vitale, V. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study. Strahlenther Onkol. 179, 464-470 (2003).
84. Clarke, R. E. et al. Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int. J. Radiat. Oncol. Biol. Phys. 72, 134-143 (2008).
85. Ben-Josef, E. et al. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. Semin. Radiat. Oncol. 12, 81-85 (2002).
86. Salvemini, D., Riley, D. P. & Cuzzocrea, S. SOD mimetics are coming of age. Nat Rev. Drug Discov. 1, 367-374 (2002).
87. Berbee, M. et al. Y-Tocotrienol ameliorates ntestinal radiation injury and reduces vascular oxidative stress after total-body irradiation by an HMG-CoA reductase-dependent mechanism. Radiat. Res. 171, 596-605 (2009).
88. Boerma, M. et al. Local administration of nterleukin-11 ameliorates intestinal radiation njury in rats. Cancer Res. 67, 9501-9506 (2007).
89. Booth, C, Booth, D., Williamson, S., Demchyshyn, L. L. & Potten, C. S. Teduglutide (Gly2GLP-2) protects small intestinal stem cells from radiation damage. Cell. Prolif. 37, 385-400 (2004).
90. Cai, Y et al. Keratinocyte growth factor pretreatment prevents radiation-induced ntestinal damage in a mouse model. Scand. J. Gastroenterol. 48, 419-426 (2013).
91. Bhanja, P. et al. Protective role of R.-spondin1, an intestinal stem cell growth factor, against radiation-induced gastrointestinal syndromen mice. PLoS ONE 4, e8014 (2009).
92. de Lau, Wim B M, Snel, B. & Clevers, H. C. The R.-spondin protein family. Genome Biol. 13, 242 (2012).
93. Khan, W. B., Shui, C, Ning, S. & Knox, S. J. Enhancement of murine intestinal stem cel survival after irradiation by keratinocyte growth factor. Radiat. Res. 148, 248-253 (1997).
94. Matthews, M. A., Watkins, D., Darbyshire, A., Carson, W. E. & Besner, G. E. Heparin-binding EGF-ike growth factor (HB-EGF) protects the intestines from radiation therapy-induced intestinal injury. J. Pediatr. Surg. 48, 1316-1322 (2013).
95. Torres, S. et al. Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat. Int. J. Radiat. Oncol. Biol. Phys. 69, 1563-1571 (2007).
96. Zhou, W.-J., Geng, Z. H., Spence, J. R. & Geng, J.-G. Induction of intestinal stem cells by R.-spondin 1 and Slit2 augments chemoradioprotection. Nature 501, 107-111 (2013).
97. Fu, Q. et al. The somatostatin analog SOM230 (pasireotide) ameliorates injury of the intestinal mucosa and increases survival after total-body rradiation by inhibiting exocrine pancreatic secretion. Radiat. Res. 171, 698-707 (2009).
98. Fu, Q. et al. Preclinical evaluation of Som230 as a radiation mitigator in a mouse model: postexposure time window and mechanisms of action. Radiat Res. 175, 728-735 (2011).
99. Burdelya, L. G. et al. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320, 226-230 (2008).
100. Deng, W. et al. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation-and chemotherapy-induced apoptosis. Gastroenterology 123, 206-216 (2002).
101. Deng, W. et al. The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology 132, 1834-1851 (2007).
102. Saha, S. et al. TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome. PLoS ONE 7, e29357 (2012).
103. Shakhov, A. N. et al. Prevention and mitigation of acute radiation syndrome in mice by synthetic ipopeptide agonists of Toll-like receptor 2 (TLR2). PLoS ONE 7, e33044 (2012).
104. Singh, V. K. et al. CBLB613: a TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure. Radiat. Res. 177, 628-642 (2012).
105. Movsas, B. et al. Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin. Cancer Res. 17, 222-228 (2011).